BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chew SA, Moscato S, George S, Azimi B, Danti S. Liver Cancer: Current and Future Trends Using Biomaterials. Cancers (Basel) 2019;11:E2026. [PMID: 31888198 DOI: 10.3390/cancers11122026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Solaipriya S, Mahalakshmi N, Prajitha R, Sivaramakrishnan V. In Vivo, Ex Vivo, and In Vitro Model Systems for Liver Cancer Research. Handbook of Animal Models and its Uses in Cancer Research 2023. [DOI: 10.1007/978-981-19-3824-5_19] [Reference Citation Analysis]
2 Hyung Soon Lee, Joon Ye Kim, Simon Weonsang Ro, Myoung Soo Kim, Haeryoung Kim, Dong Jin Joo. Antitumor Effect of Low-Dose of Rapamycin in a Transgenic Mouse Model of Liver Cancer. Yonsei Med J 2022;63. [PMID: 36303309 DOI: 10.3349/ymj.2022.0247] [Reference Citation Analysis]
3 Sharma A, Cressman E, Attaluri A, Kraitchman DL, Ivkov R. Current Challenges in Image-Guided Magnetic Hyperthermia Therapy for Liver Cancer. Nanomaterials (Basel) 2022;12. [PMID: 36014633 DOI: 10.3390/nano12162768] [Reference Citation Analysis]
4 Wang YQ, Huang C, Ye PJ, Long JR, Xu CH, Liu Y, Ling XL, Lv SY, He DX, Wei H, Yu CY. Prolonged blood circulation outperforms active targeting for nanocarriers-mediated enhanced hepatocellular carcinoma therapy in vivo. J Control Release 2022;347:400-13. [PMID: 35577150 DOI: 10.1016/j.jconrel.2022.05.024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Ding J, Tang B, Liu X, Bai X, Wang Y, Li S, Li J, Liu M, Wang X. Excretory-secretory product of Trichinella spiralis inhibits tumor cell growth by regulating the immune response and inducing apoptosis. Acta Trop 2022;225:106172. [PMID: 34627760 DOI: 10.1016/j.actatropica.2021.106172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jordan EM, Milazzo M, Chew SA, Danti S. Biomaterials and devices for immunotherapy. Engineering Technologies and Clinical Translation 2022. [DOI: 10.1016/b978-0-323-90949-5.00004-8] [Reference Citation Analysis]
7 Chowdhury MMH, Salazar CJJ, Nurunnabi M. Recent advances in bionanomaterials for liver cancer diagnosis and treatment. Biomater Sci 2021;9:4821-42. [PMID: 34032223 DOI: 10.1039/d1bm00167a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Negrete M, Romero-ben E, Gutiérrez-valencia A, Rosales-barrios C, Alés E, Mena-barragán T, Flores JA, Castillejos MC, de la Cruz-ojeda P, Navarro-villarán E, Cepeda-franco C, Khiar N, Muntané J. PDA-Based Glyconanomicelles for Hepatocellular Carcinoma Cells Active Targeting Via Mannose and Asialoglycoprotein Receptors. ACS Appl Bio Mater 2021;4:4789-4799. [DOI: 10.1021/acsabm.0c01679] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 13.5] [Reference Citation Analysis]
10 Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 2021;11:5464-90. [PMID: 33859758 DOI: 10.7150/thno.54822] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
11 Svozilová H, Plichta Z, Proks V, Studená R, Baloun J, Doubek M, Pospíšilová Š, Horák D. RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model. Int J Mol Sci 2021;22:2376. [PMID: 33673496 DOI: 10.3390/ijms22052376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Maeda S, Hikiba Y, Fujiwara H, Ikenoue T, Sue S, Sugimori M, Matsubayashi M, Kaneko H, Irie K, Sasaki T, Chuma M. NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice. Cancer Sci 2021;112:1471-80. [PMID: 33506599 DOI: 10.1111/cas.14828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hasbum A, Quintanilla J, Jr JAA, Ding MH, Levy A, Chew SA. Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents. Future Med Chem 2021;13:393-418. [PMID: 33399488 DOI: 10.4155/fmc-2020-0289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Silva JV, Santos SDS, Sanches LM, Ferreira EI, Giarolla J. Advances in targeted dendrimers for cancer therapy and challenges for clinical translation. Dendrimer-Based Nanotherapeutics 2021. [DOI: 10.1016/b978-0-12-821250-9.00003-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Morouço P, Azimi B, Milazzo M, Mokhtari F, Fernandes C, Reis D, Danti S. Four-Dimensional (Bio-)printing: A Review on Stimuli-Responsive Mechanisms and Their Biomedical Suitability. Applied Sciences 2020;10:9143. [DOI: 10.3390/app10249143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Pérez-López A, Martín-Sabroso C, Torres-Suárez AI, Aparicio-Blanco J. Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom. Pharmaceutics 2020;12:E1028. [PMID: 33126622 DOI: 10.3390/pharmaceutics12111028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Jia W, Wang L. Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity. Evid Based Complement Alternat Med 2020;2020:9843486. [PMID: 32595757 DOI: 10.1155/2020/9843486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]